SANA Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information on How to Lead the Class Action Against Sana Biotechnology, Inc.

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for allegedly misleading investors regarding its financial stability and product development capabilities [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain operations and advance its product candidates [2]. - Specific product candidates, including SC291 in oncology, SC379, and SG299, were reportedly less promising than what the company had communicated to investors [2]. - To conserve cash and focus on more promising candidates, Sana was likely to reduce funding for or discontinue certain projects and significantly cut its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to sustain operations and advance existing product candidates [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by May 20, 2025 [3]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3]. Group 3: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].